Structural brain changes and cognition in relation to markers of vascular dysfunction

Neurobiology of Aging

Volumn 33, Issue 5, 2012, Pages 1003.e9-1003.e17

  Miralbell, Julia ^a   Soriano, Juan José ^a   Spulber, Gabriela ^b   López Cancio, Elena ^c   Arenillas, Juan Francisco ^d   Bargalló, Núria ^e   Galán, Amparo ^f   Barrios, Maria Teresa ^a   Cáceres, Cynthia ^c   Alzamora, Maria Teresa ^g   Pera, Guillem ^g   Kivipelto, Miia ^b   Wahlund, Lars Olof ^h   Dávalos, Antoni ^c   Mataró, Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cerebrovascular disease; Fibrinolysis; Inflammation; MRI; Risk factors; White matter

Indexed keywords

C REACTIVE PROTEIN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN;

ADULT; AGE; AGED; ARTICLE; BRAIN SIZE; C REACTIVE PROTEIN BLOOD LEVEL; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; COORDINATION DISORDER; DIFFUSION TENSOR IMAGING; DISEASE MARKER; FEMALE; FRACTIONAL ANISOTROPY; FRONTAL LOBE; GRAY MATTER; HUMAN; LIPOPROTEIN A BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NEUROANATOMY; PATHOLOGICAL ANATOMY; PLASMINOGEN ACTIVATOR INHIBITOR 1 BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTIN BLOOD LEVEL; RISK FACTOR; SEX; SUBCORTEX; TEMPORAL LOBE; VISUOMOTOR COORDINATION; WHITE MATTER;

EID: 85052410583     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.020     Document Type: Article

References (45)

1. Arenillas J.F., Alvarez-Sabín J., Molina C.A., Chacón P., Fernández-Cadenas I., Ribó M., Delgado P., Rubiera M., Penalba A., Rovira A., Montaner J. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke 2008, 39:1456-1463.
2. Arenillas J.F., Alvarez-Sabín J., Molina C.A., Chacón P., Montaner J., Rovira A., Ibarra B., Quintana M. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003, 34:2463-2468.
3. Arenillas J.F., Molina C.A., Chacón P., Rovira A., Montaner J., Coscojuela P., Sánchez E., Quintana M., Alvarez-Sabín J. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology 2004, 63:27-32.
4. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
5. Bowler J.V., Gorelick P.B. Advances in vascular cognitive impairment. Stroke 2009, 40:e315-e318.
6. Delano-Wood L., Bondi M.W., Jak A.J., Horne N.R., Schweinsburg B.C., Frank L.R., Wierenga C.E., Delis D.C., Theilmann R.J., Salmon D.P. Stroke risk modifies regional white matter differences in mild cognitive impairment. Neurobiol. Aging 2010, 31:1721-1731.
7. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
8. Folstein M.F., Robins L.N., Helzer J.E. The Mini-Mental State Examination. Arch. Gen. Psychiatry 1983, 40:812.
9. Fornage M., Chiang Y.A., O'Meara E.S., Psaty B.M., Reiner A.P., Siscovick D.S., Tracy R.P., Longstreth W.T. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: The cardiovascular health study. Stroke 2008, 39:1952-1959.
10. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., Rogers J., Siemers E., Trojanowski J.Q. Biological markers for therapeutic trials in alzheimer's disease. Proceedings of the biological Markers Working Group; NIA Initiative on Neuroimaging in Alzheimer's Disease. Neurobiol. Aging 2003, 24:521-536.
11. Gorelick P.B., Scuteri A., Black S.E., Decarli C., Greenberg S.M., Iadecola C., Launer L.J., Laurent S., Lopez O.L., Nyenhuis D., Petersen R.C., Schneider J.A., Tzourio C., Arnett D.K., Bennett D.A., Chui H.C., Higashida R.T., Lindquist R., Nilsson P.M., Roman G.C., Sellke F.W., Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:2672-2713. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia.
12. Gouw A.A., Seewann A., Vrenken H., van der Flier W.M., Rozemuller J.M., Barkhof F., Scheltens P., Geurts J.J. Heterogeneity of white matter hyperintensities in alzheimer's disease: Post-mortem quantitative MRI and neuropathology. Brain 2008, 131:3286-3298.
13. Hoshi T., Kitagawa K., Yamagami H., Furukado S., Hougaku H., Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005, 36:768-772.
14. Hoth K.F., Tate D.F., Poppas A., Forman D.E., Gunstad J., Moser D.J., Paul R.H., Jefferson A.L., Haley A.P., Cohen R.A. Endothelial function and white matter hyperintensities in older adults with cardiovascular disease. Stroke 2007, 38:308-312.
15. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010, 120:287-296.
16. Kennedy K.M., Raz N. Aging white matter and cognition: Differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia 2009, 47:916-927.
17. Knopman D.S., Roberts R. Vascular risk factors: Imaging and neuropathologic correlates. J. Alzheimers Dis 2010, 20:699-709.
18. Laurin D., David Curb J., Masaki K.H., White L.R., Launer L.J. Midlife C-reactive protein and risk of cognitive decline: A 31-year follow-up. Neurobiol. Aging 2009, 30:1724-1727.
19. López-Cancio E., Dorado L., Millán M., Reverté S., Suñol A., Massuet A., Mataró M., Galán A., Alzamora M., Pera G., Torán P., Dávalos A., Arenillas J.F. The population-based Barcelona-Asymptomatic Intracranial Atherosclerosis Study (ASIA): rationale and design. BMC Neurol 2011, 11:22.
20. Marrugat J., Subirana I., Comín E., Cabezas C., Vila J., Elosua R., Nam B.H., Ramos R., Sala J., Solanas P., Cordón F., Gené-Badia J., D'Agostino R.B. Validity of an adaptation of the framingham cardiovascular risk function: The VERIFICA study. J. Epidemiol. Community Health 2007, 61:40-47. VERIFICA Investigators.
21. Mori S., Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006, 51:527-539.
22. Müller M.J., Greverus D., Dellani P.R., Weibrich C., Wille P.R., Scheurich A., Stoeter P., Fellgiebel A. Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. Neuroimage 2005, 28:1033-1042.
23. Nitkunan A., Barrick T.R., Charlton R.A., Clark C.A., Markus H.S. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008, 39:1999-2005.
24. Noble J.M., Manly J.J., Schupf N., Tang M.X., Mayeux R., Luchsinger J.A. Association of C-reactive protein with cognitive impairment. Arch. Neurol 2010, 67:87-92.
25. Petito C.K. Transformation of postischemic perineuronal glial cells. I. electron microscopic studies. J. Cereb. Blood Flow Metab 1986, 6:616-624.
26. Petito C.K., Olarte J.P., Roberts B., Nowak T.S., Pulsinelli W.A. Selective glial vulnerability following transient global ischemia in rat brain. J. Neuropathol. Exp. Neurol 1998, 57:231-238.
27. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. Am. Heart J 2004, 148(1 Suppl):S19-S26.
28. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J. Med 2002, 347:1557-1565.
29. Salat D.H., Greve D.N., Pacheco J.L., Quinn B.T., Helmer K.G., Buckner R.L., Fischl B. Regional white matter volume differences in nondemented aging and alzheimer's disease. Neuroimage 2009, 44:1247-1258.
30. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: A 25-year follow-up of the honolulu-asia aging study. Ann. Neurol 2002, 52:168-174.
31. Schmidt R., Schmidt H., Pichler M., Enzinger C., Petrovic K., Niederkorn K., Horner S., Ropele S., Watzinger N., Schumacher M., Berghold A., Kostner G.M., Fazekas F. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: Results of the austrian stroke prevention study. Stroke 2006, 37:2910-2916.
32. Segura B., Jurado M.A., Freixenet N., Bargalló N., Junqué C., Arboix A. White matter fractional anisotropy is related to processing speed in metabolic syndrome patients: A case-control study. BMC Neurol 2010, 10:64.
33. Segura B., Jurado M.A., Freixenet N., Falcón C., Junqué C., Arboix A. Microstructural white matter changes in metabolic syndrome: A diffusion tensor imaging study. Neurology 2009, 73:438-444.
34. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl 1):S208-S219.
35. van Dijk E.J., Prins N.D., Vermeer S.E., Vrooman H.A., Hofman A., Koudstaal P.J., Breteler M.M. C-reactive protein and cerebral small-vessel disease: The rotterdam scan study. Circulation 2005, 112:900-905.
36. Vaughan D.E. PAI-1 and atherothrombosis. J. Thromb. Haemost 2005, 3:1879-1883.
37. Vernooij M.W., Ikram M.A., Vrooman H.A., Wielopolski P.A., Krestin G.P., Hofman A., Niessen W.J., Van der Lugt A., Breteler M.M. White matter microstructural integrity and cognitive function in a general elderly population. Arch. Gen. Psychiatry 2009, 66:545-553.
38. Vicenzini E., Ricciardi M.C., Altieri M., Puccinelli F., Bonaffini N., Di Piero V., Lenzi G.L. Cerebrovascular reactivity in degenerative and vascular dementia: a transcranial Doppler study. Eur. Neurol 2007, 58:84-89.
39. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjögren M., Wallin A., Leys A.D., Pantoni L., Pasquier F., Erkinjuntti T., Scheltens P. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001, 32:1318-1322. European Task Force on Age-Related White Matter Changes.
40. Wechsler D. WAIS, III. Weschler Adult Intelligence Scale III (Spanish Version). TEA, Madrid 1999.
41. Wersching H., Duning T., Lohmann H., Mohammadi S., Stehling C., Fobker M., Conty M., Minnerup J., Ringelstein E.B., Berger K., Deppe M., Knecht S. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010, 74:1022-1029.
42. Weuve J., Ridker P.M., Cook N.R., Buring J.E., Grodstein F. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 2006, 17:183-189.
43. Williamson J., Nyenhuis D., Stebbins G.T., Lamb D., Simkus V., Sripathirathan K., Wang C., de Toledo-Morrell L., Gorelick P. Regional differences in relationships between apparent white matter integrity, cognition and mood in patients with ischemic stroke. J. Clin. Exp. Neuropsychol 2010, 32:673-681.
44. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
45. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res 1982-1983, 17:37-49.